NeutroGen Therapeutics

NeutroGen Therapeutics (NTX) is developing a novel allogeneic neutrophil cell therapy for neutropenia—a condition prevalent in leukemia patients and individuals undergoing chemotherapy, associated with high infection risk and mortality. NTX’s patent-pending therapy uses a stem cell-based protocol that enables the produ

NeutroGen Therapeutics operates in health.

Profile

NeutroGen Therapeutics (NTX) is developing a novel allogeneic neutrophil cell therapy for neutropenia—a condition prevalent in leukemia patients and individuals undergoing chemotherapy, associated with high infection risk and mortality. NTX’s patent-pending therapy uses a stem cell-based protocol that enables the production of storable, genetically modifiable neutrophils, providing a faster, more reliable treatment. The platform also […]

NeutroGen Therapeutics is positioned in health, a segment that rewards a clear, focused offering.

It is recorded at the Creative Destruction Lab alumni company stage.

Website: www.neutrogen-therapeutics.com